Medtide

Medtide P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Medtide (3880.HK) as of Oct 17, 2026 is 12.33. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 27.36 — a change of -54.94% (lower).

P/CF

12.33

YoY

-54.94%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Medtide is 2025 12.33 . P/CF (Price-to-Cash-Flow Ratio) of Medtide was 2024 27.36 . It decreases by -54.94% lower compared to the previous year.

The Medtide P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2021
24.13 CNY
Jan 1, 2022
24.46 CNY
Jan 1, 2023
37.33 CNY
Jan 1, 2024
27.36 CNY
Jan 1, 2025
12.33 CNY
The Medtide P/CF history
YEARP/CFYoY
12.33-54.94%
27.36-26.70%
37.33+52.61%
24.46+1.35%
24.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medtide Stock analysis

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

P/CF (Price-to-Cash-Flow Ratio) of Medtide is 12.33 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Medtide changed from 27.36 to 12.33, representing a -54.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Medtide since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Medtide

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Medtide